TL;DR: Every brightening serum has to reach a layer about 60 microns deep where melanocytes sit and where pigment gets manufactured. Most do not get there in any meaningful concentration. This is the anatomy that decides whether your tyrosinase inhibitor is doing the job or just sitting on the surface, and why the strongest brightening protocols pair a topical with something that actually opens delivery into the basal layer.
I had a reader send me a photo of nine brightening products on her bathroom counter. Vitamin C, alpha arbutin, niacinamide, tranexamic acid, kojic acid, azelaic acid, a peptide blend, and two unnamed Korean serums with “whitening” on the label. She had been using a rotation of these for fourteen months and her hyperpigmentation had not moved.
I asked her one question. What did she think these products were supposed to reach?
She did not know. She had bought them on the basis of ingredient names and reviews. Nobody had told her that brightening is a problem of getting molecules to a layer of skin most products cannot penetrate well.
This is the anatomy lesson I wish someone had given me before I spent two years buying serums that never worked.
Where pigment is actually made
Your epidermis is about 100 microns thick. At the bottom of it, sitting on the basement membrane that separates epidermis from dermis, is the stratum basale, also called the basal layer. It is one cell thick. The cells that matter for pigmentation, the melanocytes, are scattered through this layer at a ratio of roughly one melanocyte per ten keratinocytes (Slominski et al., Physiological Reviews, 2004).
Each melanocyte has dendrites that reach upward like the branches of a tree. Through these dendrites it transfers melanosomes, the little organelles that contain pigment, into the surrounding keratinocytes. The keratinocytes then carry that pigment up through the stratum spinosum, stratum granulosum, and stratum corneum over about forty days, until the pigment-loaded cells reach the surface and are shed.
This means two things. First, the pigment you see on your face today was made in the basal layer about a month ago. Second, anything you apply that aims to reduce pigment production has to reach a layer 60 to 80 microns below the surface in a high enough concentration to inhibit tyrosinase, the enzyme that catalyses melanin synthesis.
Most topicals do not.
What “penetrates” actually means
The cosmetic industry uses the word penetration loosely. A serum can “penetrate” the skin in the sense that it moves into the stratum corneum, the dead-cell layer at the top, and stays there. This is not the same as reaching the basal layer.
Real penetration to the basal layer requires either small molecular size, lipid solubility, or a delivery system that opens the intercellular pathways between corneocytes. Vitamin C as L-ascorbic acid has a molecular weight of 176 daltons and is a borderline candidate. Niacinamide at 122 daltons is small enough. Kojic acid at 142 is reasonable. Tranexamic acid at 157 is fine on size but limited by its polarity.
Alpha arbutin is 272 daltons. Glutathione is 307. Most peptides are above 500. The general rule from the Bos and Meinardi work, which the dermatology community has used since 2000, is that molecules above 500 daltons do not cross the stratum corneum in meaningful concentrations. This is why so many “active” serums above that threshold show modest in-vitro results and disappointing in-vivo outcomes.
The reader with nine serums had three molecules that could reach the basal layer in workable concentrations. The other six were sitting on her stratum corneum doing essentially nothing.
What tyrosinase inhibition needs
Tyrosinase is the enzyme that converts tyrosine to dopa to dopaquinone, the committed step in melanin production. To inhibit it you need a molecule that either competes with tyrosine at the active site or chelates the copper at the enzyme’s centre. Kojic acid does the second. Arbutin and hydroquinone are tyrosine analogues. Vitamin C reduces dopaquinone back to dopa before pigment forms.
These mechanisms are not contested. They are in Briganti et al.’s 2003 review and the Solano 2006 followup. What is contested is whether the topical product you bought delivers the molecule at a concentration sufficient to inhibit the enzyme at the depth where it lives.
In vitro studies that test tyrosinase inhibition in a test tube use concentrations that bear no relationship to what reaches your basal layer through a serum. A study can show 80 percent inhibition at 1 millimolar arbutin in solution and the actual skin concentration at the basal layer from a 2 percent topical formulation might be a hundredth of that. The molecule works. The delivery does not.
Why hydroquinone still wins despite a worse reputation
Hydroquinone at 4 percent is the gold standard for melasma and hyperpigmentation in dermatology. It has been since the 1980s. Its molecular weight is 110 daltons. It is small, lipid-soluble enough to cross the corneum, and structurally similar enough to tyrosine that it competes effectively at the enzyme site.
It also has a worse safety profile than the cosmetic alternatives. Long-term use can cause exogenous ochronosis, a paradoxical darkening that is hard to reverse. The reputation has hurt it commercially in markets where it is OTC, like the United States, and it is now prescription-only in most of Europe.
The replacement molecules are safer but mostly weaker. The ones that come closest to hydroquinone’s clinical effect are azelaic acid at 15 to 20 percent (size 188 daltons, well-studied, available OTC), tranexamic acid in oral form, and the prescription combination of hydroquinone with tretinoin and a corticosteroid, known as the Kligman formula.
The Kligman formula works partly because the tretinoin opens up the delivery pathway. Retinoic acid accelerates keratinocyte turnover, thins the stratum corneum slightly, and increases the penetration of the hydroquinone into the basal layer. The corticosteroid suppresses the irritation from both.
This is the only formulation I have seen consistently deliver visible results on stubborn pigment within twelve weeks. It is also the only one that combines a tyrosinase inhibitor with a delivery enhancer. The cosmetic market has tried to imitate it for thirty years and mostly failed because the imitations replace the hydroquinone with weaker actives and skip the delivery question entirely.
What I do now for pigment
I do not use vitamin C in the morning anymore. I used it for years on the assumption that it was doing the brightening work. When I read the Briganti review carefully I found that the in-vivo studies on topical vitamin C for hyperpigmentation are mixed. The strongest data is on photoaging and antioxidant protection, not on existing pigment.
I use azelaic acid at 15 percent in the morning (Finacea or the Ordinary version, both are fine) and tretinoin 0.05 percent at night. The tretinoin is the delivery system. The azelaic acid is the tyrosinase inhibitor. I have been on this protocol for three years for residual PIH from a chemical peel I should not have done in 2021.
The pigment is about 70 percent improved. It is not gone. It will not be gone. The melanocytes that were activated by the inflammation are slow to fully deactivate, and I have accepted that the last 30 percent may need a fractional laser intervention I am not yet willing to do.
This is what a realistic basal-layer protocol looks like. Two molecules, a delivery system, and three years.
Where the marketing fails
When a serum claims “brightening” it has three options for what it actually does. It can inhibit tyrosinase if the molecule reaches the basal layer. It can increase desquamation, sloughing off pigmented corneocytes faster (acids do this). It can scatter light off the surface to make skin look brighter without changing pigment (silicones and micas do this).
The third one is the most common. A serum with no real brightening active can score well on consumer perception studies because subjects see immediate visible brightening, which is optical, not pigmentary. A week later they still have the same pigment underneath. By then they have bought a second bottle.
I am not against optical brighteners. I am against marketing that implies they are doing what they are not. If you want optical brightness, a finishing fluid with silicones and a small amount of pearl mica will work and cost ten dollars. If you want pigment reduction, you need to take the basal-layer problem seriously and pick the right molecule at the right depth.
The contrarian section: maybe you don’t need brightening
If your pigment is from sun exposure and not yet entrenched, the most effective intervention is daily SPF 30 or higher and time. Sun protection alone can reduce mild to moderate pigment by a measurable amount over twelve months because the melanocytes stop receiving the trigger that activates them.
People skip this because it is slow and it requires no purchasing. I skipped it for two years. The pigment got worse. I started wearing sunscreen daily, including the days I did not leave the house (UVA penetrates window glass), and a measurable amount of the lighter pigment faded on sunscreen alone, before I added any treatment.
The basal layer is not always the target. Sometimes the trigger is.
Frequently asked
How long until I see results from a brightening protocol? Twelve weeks minimum. The pigment you see today was made in the basal layer about thirty days ago. A new pigment-free generation of keratinocytes has to travel up before you see surface change. Anyone promising results in two weeks is selling you optical brightness.
Is niacinamide a real brightener? Yes but mild. It works by interrupting melanosome transfer from melanocytes to keratinocytes, not by inhibiting tyrosinase. It is small enough to penetrate. It will not move heavy pigment alone but adds to a stack.
Why doesn’t vitamin C work as well as the marketing claims? L-ascorbic acid is unstable, oxidises in the bottle, and at workable pH the active form is a minority of the total content. It can work but the formulations that hold up over time are a small subset of what is sold.
What is the strongest OTC brightening protocol? Azelaic acid 15 to 20 percent twice daily plus a retinoid at night plus daily sunscreen. This is the closest non-prescription approach to the Kligman framework.
Closing
The reader with nine serums has now switched to two. She uses tretinoin three nights a week and azelaic acid daily. Her pigment is moving. She emails every couple of months with photos.
The basal layer does not care which serum bottle is prettier. It cares whether the molecule got there and whether the enzyme was inhibited. Most products fail one of those tests. The ones that work are not expensive.
Linked tools to work out where you are: the hyperpigmentation type decoder, the tretinoin decoder, and the sunscreen recommendation for your skin tone.
References
- Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological Reviews, 2004. PMID: 15383650.
- Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB Journal, 2007. PMID: 17242160.
- Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Research, 2003. PMID: 12950727.
- Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Research, 2006. PMID: 17083484.
Related Elelaf tools
Sources
- Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological Reviews, 2004. PMID: 15383650.
- Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB Journal, 2007. PMID: 17242160.
- Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Research, 2003. PMID: 12950727.
- Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Research, 2006. PMID: 17083484.